"SW48人結(jié)腸腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實驗室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個容器轉(zhuǎn)移到另一個容器的過程，以擴大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

H510A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代；每周換液２次。;生長特性：混合生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：DHL-5細(xì)胞、PLB 985細(xì)胞、COLO-741細(xì)胞

OVCA 432 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：YES2細(xì)胞、NT-2細(xì)胞、HOC細(xì)胞

NCI-H2009 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：CHP 212細(xì)胞、LS 174T細(xì)胞、WEHI3細(xì)胞

SW48人結(jié)腸腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見相關(guān)文獻(xiàn)介紹

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

絕大部分細(xì)胞消化只要用胰酶潤洗一遍即可：吸去胰酶后，殘留的那些無法計算體積的附著在細(xì)胞表面的微量胰酶在37℃一般不到2min足夠消化細(xì)胞(絕大部分1min不到)。對于這些細(xì)胞原則上不要用胰酶孵育細(xì)胞，連續(xù)這樣傳代，對細(xì)胞傷害很大。簡單的程序是PBS潤洗吸去，胰酶潤洗吸去，然后37℃消化。什么算是消化好了呢？不需要把細(xì)胞全部消化成間隔分布很離散的單個圓形才算消化好了，一般你肉眼觀察貼壁細(xì)胞層，只要能移動了，多半呈沙狀移動，其實已經(jīng)是可以了。一般能移動了，說明細(xì)胞與培養(yǎng)基質(zhì)材料的附著已經(jīng)消失了，細(xì)胞之間的附著也已經(jīng)消失了，細(xì)胞已經(jīng)獨立分布了(雖然沒有呈現(xiàn)很廣的離散分布)。這個時候應(yīng)該停止消化，不要等到看到鏡下所有細(xì)胞都分離得非常好，間隙很大，才停止。細(xì)胞系在貼壁的過程中仍然會聚集，這個是貼壁培養(yǎng)的細(xì)胞，尤其是腫瘤細(xì)胞的一個特性，你可以嘗試，準(zhǔn)備100%的單個細(xì)胞懸液，貼壁后觀察細(xì)胞，仍然是幾個幾個細(xì)胞聚集在一起。一些懸浮培養(yǎng)細(xì)胞也是如此，容易聚集，不要過幾個小時就拿出來吹打成單細(xì)胞懸液。細(xì)胞只要能從基質(zhì)上脫離下來，即使是成片的(比如Calu-3細(xì)胞)，吹打不超過20次(一般10次即可)，成小規(guī)模聚集(10個細(xì)胞左右)是正常的，不要再去延長消化時間，等待單細(xì)胞懸液出現(xiàn)。比較難消化的細(xì)胞：潤洗方法5min還不能消化，以結(jié)腸癌細(xì)胞為例，比如：HCT15、LS411和KM12細(xì)胞，胰酶消化，一般10 cm培養(yǎng)皿，一次加入300ul-500ul就足夠了。即使這樣難消化的細(xì)胞，一般不超過5min，即可見細(xì)胞成片移動，就應(yīng)該停止消化。一些正常細(xì)胞也會有難消化的時候，比如tsDC細(xì)胞，用胰酶孵育，3min左右即可看到成片沙狀移動。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

SW48人結(jié)腸腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

NRCC Cells;背景說明：腎透明細(xì)胞癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Fu97細(xì)胞、8505C細(xì)胞、COLO320HSR細(xì)胞

Eca-109 Cells;背景說明：１９７３年建系，來自人食管中段鱗癌組織，小塊法原代培養(yǎng)建系。BALB/c裸鼠移植成瘤。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SKMEL1細(xì)胞、F-36P細(xì)胞、HCMEC(BL12-H)細(xì)胞

H4-II-E-C3 Cells;背景說明：在糖皮質(zhì)激素、胰島素或cAMP衍生物的誘導(dǎo)下可以產(chǎn)生酪酸基轉(zhuǎn)移酶；可被逆轉(zhuǎn)錄病毒感染；可產(chǎn)生白蛋白、轉(zhuǎn)鐵蛋白、凝血酶原；在AxC大鼠中可以成瘤。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Mel-624細(xì)胞、CESS細(xì)胞、THEECs細(xì)胞

DU 145 Cells;背景說明：DU １４５ 是從一位有３年淋巴細(xì)胞白血病史的前列腺癌患者的腦部轉(zhuǎn)移灶中建立的。該細(xì)胞系未檢測到激素敏感性，酸性酶陽性，單個的細(xì)胞可在軟瓊脂中形成集落。對此細(xì)胞和原始腫瘤的亞顯微結(jié)構(gòu)分析可見微絨毛、微絲、細(xì)胞橋粒、線粒體、發(fā)達(dá)的高爾基體和異質(zhì)溶酶體。該細(xì)胞不表達(dá)前列腺抗原。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Fetal Human Lens-124細(xì)胞、McA-RH 8994細(xì)胞、U118-MG細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

貼壁消化難題：１，先用PBS 把細(xì)胞洗兩遍，使瓶內(nèi)沒有血清了，減少對胰酶的中和，然后用新配的０.２５%的胰酶加入３ml左右，放在３７度，然后可以在細(xì)胞有些消化下來時，拿著瓶口，運用手腕的力量輕輕震蕩瓶內(nèi)體，這樣細(xì)胞很快就下來了，還不需要吹打，分散也均勻；２，成團(tuán)、絮狀：消化里加入eda可以減少細(xì)胞成團(tuán)的現(xiàn)象，血清可以終止胰酶的作用，如果是進(jìn)口血清的話也能終止eda的作用。用胰酶消化后胰酶可以倒掉，也可以不倒，直接加血清終止，如果消化中加入了eda的話，就要將消化倒干凈，如果細(xì)胞貼壁要求不是很嚴(yán)格的話，一般不需要進(jìn)行離心。鼻咽癌細(xì)胞的貼壁能力很強，用０.５%胰酶(含０.１%EDA)一般要消化１２~１５min。用PBS洗滌時要洗凈殘余的培養(yǎng)基，加入胰酶后在培養(yǎng)箱中消化(避免細(xì)胞室溫下受損以及在此溫度時胰酶活性Zui強)至細(xì)胞收縮變圓(可顯微鏡下觀察)且有少許細(xì)胞脫落(有流下來的趨勢)，隨后立即棄去胰酶(如果脫落的細(xì)胞很多且需要大量細(xì)胞實驗，則不能棄去胰酶)，加入培養(yǎng)基仔細(xì)吹打(不能用無血清培養(yǎng)基或者PBS替代，否則細(xì)胞聚集成團(tuán)塊或絮狀)。一般我都離心一次棄去上清(去除殘留的胰酶及漂浮的死細(xì)胞或細(xì)胞碎片)；消化過度：馬上用培養(yǎng)基中和，用吸管吹打細(xì)胞，收集全部的細(xì)胞到以無菌的離心管中８００RPM ３分鐘。棄上清，用全培重懸，換新的培養(yǎng)瓶繼續(xù)培養(yǎng)，狀態(tài)不HAO的細(xì)胞在培養(yǎng)的過程中會死亡脫落，在換的時候可以清除掉！

H196 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM-2664細(xì)胞、HcaF細(xì)胞、GM01232細(xì)胞

U343 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK AD293細(xì)胞、FO [Mouse myeloma]細(xì)胞、SKNBE(2)細(xì)胞

MDAPCa-2b Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：TOV-112D細(xì)胞、U-373MG細(xì)胞、HS-683細(xì)胞

P3/NS1/1-Ag4.1 Cells;背景說明：這是P３X６３Ag８(ATCCTIB-９)的一個不分泌克隆。Kappa鏈合成了但不分泌。能抗０.１mM８-氮雜鳥嘌呤但不能在HAT培養(yǎng)基中生長。據(jù)報道它是由于缺失了３-酮類固醇還原酶活性的膽固醇營養(yǎng)缺陷型。檢測表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代，３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：H2444細(xì)胞、IR 983F細(xì)胞、LC1細(xì)胞

PC3-M Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs 611.T細(xì)胞、H-647細(xì)胞、HO-8910細(xì)胞

LS 174T Cells;背景說明：LS １７４T是LS １８０ (ATCC CL １８７)結(jié)腸腺癌細(xì)胞株的胰蛋白酶化變種。 它比親本更易傳代，象LS １８０一樣生成大量的癌胚抗原(CEA)。 電鏡研究表明有豐富的微絲和細(xì)胞質(zhì)粘液素液泡。 直腸抗原３陽性。 p５３抗原表達(dá)陰性，但mRNA表達(dá)陽性。 與ATCC CL-１８７來源于同一個腫瘤。LS １７４T細(xì)胞角蛋白染色陽性。 癌基因c-myc, N-myc, H-ras, N-ras, Myb, 和 fos的表達(dá)呈陽性。 癌基因k-ras和sis的表達(dá)未做檢測。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HS 445T細(xì)胞、P3-NS1/1-Ag4-1細(xì)胞、L 540細(xì)胞

PCI-4B Cells;背景說明：喉鱗癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GDM-1細(xì)胞、NUGC4細(xì)胞、HUT125細(xì)胞

FaDu Cells;背景說明：１９６８年從一位印度下咽骨腫瘤患者的鉆孔活組織切片中建立了FaDu細(xì)胞株。在建立的細(xì)胞株中發(fā)現(xiàn)細(xì)胞質(zhì)中含有成束的細(xì)絲，并且細(xì)胞分界上的橋粒特別突出。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Farage細(xì)胞、D-407細(xì)胞、SK-MES-1細(xì)胞

GDM-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：MCF7-GFP細(xì)胞、B16 melanoma F10細(xì)胞、UWB1289細(xì)胞

624 Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCMEC細(xì)胞、D10.G4.1細(xì)胞、CMT 64細(xì)胞

H1836 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1581細(xì)胞、MUGCHOR1細(xì)胞、GM00215A細(xì)胞

Hk-2 Cells;背景說明：該細(xì)胞屬源于正常腎的近曲小管細(xì)胞，通過導(dǎo)入HPV-１６ E６/E７基因而獲得永生化。將含有HPV-１６ E６/E７基因的重組的逆轉(zhuǎn)錄病毒載體pLXSN １６ E６/E７轉(zhuǎn)染外生包裝細(xì)胞Psi-２，Psi-２細(xì)胞產(chǎn)生的病毒再去感染兼嗜性包裝細(xì)胞系PA３１７，最后將PA３１７產(chǎn)生的病毒顆粒導(dǎo)入正常的腎皮質(zhì)近曲小管細(xì)胞。盡管pLXSN １６ E６/E７中含有新霉素抗性，但未用G４１８篩選轉(zhuǎn)導(dǎo)克隆。Southern和FISH分析顯示HK-２細(xì)胞來源于單克隆。PCR檢測證實HK-２細(xì)胞基因組中含有E６/E７基因。;傳代方法：１：４傳代；２-３天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：B5537SKIN細(xì)胞、BT20細(xì)胞、PC-10細(xì)胞

Granta 519 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HET-1A細(xì)胞、J 774A.1細(xì)胞、Central Adrenergic TH-expressing a細(xì)胞

F56 [Human neoplasm] Cells;背景說明：F５６是一株人的腺癌細(xì)胞系，可用于腺癌發(fā)生機制的研究，也可用于抗癌藥物的篩選。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：CL-11細(xì)胞、PANC-02-03細(xì)胞、TE-85 clone 5細(xì)胞

McA-RH8994 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LAN1細(xì)胞、PL-45細(xì)胞、Mel624細(xì)胞

HSC5 Cells;背景說明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW 900細(xì)胞、AR42J細(xì)胞、H-510A細(xì)胞

RPTC Cells;背景說明：腎小管；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MES13細(xì)胞、293A細(xì)胞、M.D. Anderson-Prostate Cancer-2b細(xì)胞

Abcam HEK293T ARHGDIA KO 1 Cells(提供STR鑒定圖譜)

AG09095 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line LRY015 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC201 Cells(提供STR鑒定圖譜)

Bre-40 Cells(提供STR鑒定圖譜)

COLO 357-TRS4 Cells(提供STR鑒定圖譜)

DA03895 Cells(提供STR鑒定圖譜)

DA06471 Cells(提供STR鑒定圖譜)

GM01023 Cells(提供STR鑒定圖譜)

SW620 Cells;背景說明：SW６２０是從一個５１歲男性白人組織中分離得到。由A.Leibovitz等從一個淋巴結(jié)建株。細(xì)胞系主要由無絨毛的小園球細(xì)胞和雙極細(xì)胞組成。它僅合成少量癌胚抗原（CEA）且在裸鼠中有高度的致瘤性;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Granta 519細(xì)胞、MD Anderson-Metastatic Breast-436細(xì)胞、Vero-76細(xì)胞

SW48人結(jié)腸腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

LC-2/ad Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE-85 clone 5細(xì)胞、SDBMSC細(xì)胞、AG 9細(xì)胞

HTR-8 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H2330細(xì)胞、MDA-157細(xì)胞、V 79細(xì)胞

NCI H548 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC 38細(xì)胞、MDAMB175VII細(xì)胞、AQ-Mel細(xì)胞

RCC-4 Cells;背景說明：腎透明細(xì)胞癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A549細(xì)胞、KPL1細(xì)胞、COLO 320 HSR細(xì)胞

HCC 70 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Nthy-ori 3-1細(xì)胞、SK-MEL28細(xì)胞、AC16 [Human hybrid]細(xì)胞

30Q8A Cells(提供STR鑒定圖譜)

SK-N-BE-2c Cells;背景說明：神經(jīng)母細(xì)胞瘤；骨髓轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1915細(xì)胞、Human Foreskin Fibroblast細(xì)胞、ABC-1細(xì)胞

PANC-04-03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MPC-83細(xì)胞、ADR-RES細(xì)胞、H-II-E-C3細(xì)胞

Factor Dependent Cell-Paterson 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：HeLa S-3細(xì)胞、RPMI-8402細(xì)胞、G-Olig2細(xì)胞

HepG2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Centre Antoine Lacassagne-148細(xì)胞、Primary Liver Carcinoma/Poliomyelitis Research Foundation/5細(xì)胞、JKT1細(xì)胞

EST50 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：CCD-1095Sk細(xì)胞、GLRK 13細(xì)胞、SKES1細(xì)胞

Rat podocyte Cells;背景說明：腎；足 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM 239-A細(xì)胞、HCC2185細(xì)胞、CHL-1細(xì)胞

EST50 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：CCD-1095Sk細(xì)胞、GLRK 13細(xì)胞、SKES1細(xì)胞

HAEC Cells;背景說明：主動脈；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Baby Hamster Kidney 21細(xì)胞、A-72細(xì)胞、DU4475細(xì)胞

GM12566 Cells(提供STR鑒定圖譜)

HAP1 EPHB3 (-) Cells(提供STR鑒定圖譜)

U-266 AR1 Cells;背景說明：骨髓瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DI TNC1細(xì)胞、SU86.86細(xì)胞、H1819細(xì)胞

KM.12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HFLS細(xì)胞、GM02131細(xì)胞、SK HEP 01細(xì)胞

Farage OL Cells;背景說明：Farage細(xì)胞源于一名患有彌漫性大B細(xì)胞淋巴瘤(DLBCL）白人女性的活檢淋巴組織，由HBen-Bassat建系。經(jīng)IL-４處理，該細(xì)胞CD２１,CD２２,CD５４和CD５８表達(dá)上調(diào)，而CD２１,CD２２,andCD３８表達(dá)下調(diào)。;傳代方法：１：３傳代,２-３天傳一代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：F-36P細(xì)胞、SK-RC 52細(xì)胞、SK-MEL5細(xì)胞

MDA-MB-134-VI Cells;背景說明：該細(xì)胞１９７３年由R. Cailleau建系，源自７４歲乳腺導(dǎo)管癌女性患者的胸腔積液，細(xì)胞生長緩慢，松散貼壁，生長過程中會脫落到培養(yǎng)基，不會匯合，過表達(dá)FGF受體;傳代方法：１：２—１：４傳代，每周換液２—３次;生長特性：松散貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MDA-MB436細(xì)胞、TGW-nu細(xì)胞、RAOEC細(xì)胞

HeLa S3 Cells;背景說明：該細(xì)胞是１９５５年由PuckTT,MarcusPI和CieciuraSJ建系的，含HPV-１８序列；角蛋白陽性；可用于與染色體突變、細(xì)胞營養(yǎng)、集落形成相關(guān)的哺乳動物細(xì)胞的克隆分析。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H82細(xì)胞、H676B細(xì)胞、Mink細(xì)胞

LA-N-5 Cells;背景說明：神經(jīng)母細(xì)胞瘤；骨髓轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Merwin Plasma Cell tumor-11細(xì)胞、NIH:OVCAR-8細(xì)胞、LAD-2細(xì)胞

GM-346 Cells;背景說明：皮下結(jié)締組織；自發(fā)永生；雄性；C３H/An;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVHM細(xì)胞、KM H-2細(xì)胞、NBLS細(xì)胞

HCC-1569 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４—１：６傳代，每周換液２—３次;生長特性：混合生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：WSUDLCL2細(xì)胞、AN3 CA細(xì)胞、Hs606T細(xì)胞

HiPS-RIKEN-13A Cells(提供STR鑒定圖譜)

iPS CWRU1 Cells(提供STR鑒定圖譜)

MB-KG Cells(提供STR鑒定圖譜)

ND10499 Cells(提供STR鑒定圖譜)

PL [Sardinops] Cells(提供STR鑒定圖譜)

tsJT60 Cells(提供STR鑒定圖譜)

ULK1+ULK2 DKO MEF (SV40) Cells(提供STR鑒定圖譜)

HAX1corrected-iPSC#1 Cells(提供STR鑒定圖譜)

MCF/Adr Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BE(2)M-17細(xì)胞、BEL-7404細(xì)胞、CCC-ESF-1細(xì)胞

H-446 Cells;背景說明：該細(xì)胞是１９８２年由CarneyD和GazdarAF等從一位小細(xì)胞肺癌患者的胸腔積液中建立的。細(xì)胞的原始形態(tài)并不具有小細(xì)胞肺癌特征。這個細(xì)胞株是小細(xì)胞肺癌的生化和形態(tài)學(xué)上的變種，表達(dá)神經(jīng)元特有的烯醇酶和腦型肌酸激酶同工酶；左旋多巴脫羧酶、蠶素、抗利尿激素、催產(chǎn)素或胃泌激素釋放肽未達(dá)到可檢測水平。與正常細(xì)胞相比，該細(xì)胞c-mycDNA序列擴增約２０倍，RNA增加１５倍。最初傳代培養(yǎng)基用含有５%FBS的RPMI１６４０，另外添加１０nM化可的松、０.００５mg/ml胰島素、０.０１mg/ml轉(zhuǎn)鐵;傳代方法：１：２傳代;生長特性：貼壁/懸浮生長，混合;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：U251-MG細(xì)胞、Hs 888.T細(xì)胞、A9(Hamprecht)細(xì)胞

H-2106 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Japanese Tissue Culture-39細(xì)胞、SBC-5細(xì)胞、C4 I細(xì)胞

HL-60 Clone 15 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：維持細(xì)胞濃度在１×１０５-１×１０６/ml,每２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HHUA細(xì)胞、Roswell Park Memorial Institute 7666細(xì)胞、TE-6細(xì)胞

NCIH2141 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Large Cell Lung Cancer-103H細(xì)胞、BJAB-1細(xì)胞、MESSA-DX5細(xì)胞

P3X63 Ag8.653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Factor Dependent Cell-Paterson 1細(xì)胞、HHL-5細(xì)胞、MDA231-LM2-4175細(xì)胞

ID8/MOSEC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：QGP1細(xì)胞、NCIN87細(xì)胞、ADR-RES細(xì)胞

H1666 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長，松散;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Hs 888.Lu細(xì)胞、H-2122細(xì)胞、LA795細(xì)胞

NRK49F Cells;背景說明：腎；成纖維細(xì)胞；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SN4741細(xì)胞、GM04678細(xì)胞、3T3-L1 ad細(xì)胞

THP-1 Cells;背景說明：該細(xì)胞從一名１歲的患有急性單核細(xì)胞性白血病的男孩的外周血中分離建立。該細(xì)胞可以吞噬乳膠顆粒和激活的紅細(xì)胞，細(xì)胞膜和胞漿內(nèi)均沒有免疫球蛋白，表達(dá)C３R和FcR；可受佛波酯TPA誘導(dǎo)向單核系方向分化；可作為轉(zhuǎn)染宿主。;傳代方法：維持細(xì)胞濃度在２-４×１０５-８×１０５/ml，勿超過１×１０６/ml；２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：單核細(xì)胞;相關(guān)產(chǎn)品有：OVCAR420細(xì)胞、P388-D1細(xì)胞、High Five細(xì)胞

P3-x63-Ag8 653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H23細(xì)胞、NCIH2126細(xì)胞、MV3細(xì)胞

P3-X63-Ag8-653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H250細(xì)胞、JKT1細(xì)胞、SJSA細(xì)胞

SK-ChA-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CHL細(xì)胞、PC-3細(xì)胞、TOV-112D細(xì)胞

H250 Cells;背景說明：小細(xì)胞肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：半貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VM-CUB1細(xì)胞、RERF-LC-MS細(xì)胞、NU-GC-2細(xì)胞

RCK-8 Cells;背景說明：彌漫大B淋巴瘤；腹腔轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：University of Arizona Cell Culture-893細(xì)胞、WC00079細(xì)胞、RPMI 7666細(xì)胞

SG237R Cells(提供STR鑒定圖譜)

BL1339 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：L363細(xì)胞、OVISE細(xì)胞、H-358細(xì)胞

HCC-78 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H358細(xì)胞、RPMC細(xì)胞、L-Wnt-3A細(xì)胞

NCIH526 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長 ;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Panc8.13細(xì)胞、WERI Rb-1細(xì)胞、ATC241細(xì)胞

OCM-1A Cells;背景說明：脈絡(luò)膜黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A.704細(xì)胞、Bronchial Epithelium transformed with Ad12-SV40 2B細(xì)胞、OCILY3細(xì)胞

Fukuoka University-Malignant mixed Mullerian Tumor-1 Cells;背景說明：子宮肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs600T細(xì)胞、NCI-SNU-182細(xì)胞、NRK clone 52E細(xì)胞

SW-1116 Cells;背景說明：CSAp陰性(CSAp-)。 結(jié)腸抗原３，陰性。 角蛋白免疫過氧化物酶染色陽性。 癌基因c-myc, K-ras, H-ras, myb, sis 和fos的表達(dá)呈陽性。 未檢測到癌基因N-myc和N-ras的表達(dá)。 表達(dá)腫瘤特異的核基質(zhì)蛋白CC-４，CC-５和CC-６。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：CL1細(xì)胞、Transformed Human Liver Epithelial-3細(xì)胞、MODE-K細(xì)胞

SW48人結(jié)腸腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

WM239A Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC-3M-IE8細(xì)胞、OVCAR420細(xì)胞、TCMK1細(xì)胞

CORL51 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1299細(xì)胞、CF Pac1細(xì)胞、Hs746-T細(xì)胞

Intestinal Epithelioid Cell line No. 18 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hx-147細(xì)胞、H510A細(xì)胞、NIH:OVCAR3細(xì)胞

EA.Hy926 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H1770細(xì)胞、H-2029細(xì)胞、HEK293F細(xì)胞

D10 Cells;背景說明：T淋巴細(xì)胞；AKR/J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HDLM2細(xì)胞、COR-L26細(xì)胞、Vx-2細(xì)胞

IOSE80 Cells;背景說明：卵巢；上皮細(xì)胞；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H69C細(xì)胞、LLC1細(xì)胞、Panc3_27細(xì)胞

Rin-M-5F Cells;背景說明：胰島β細(xì)胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H748細(xì)胞、L M (TK-)細(xì)胞、MBT2細(xì)胞

SUM-149PT Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OsACL細(xì)胞、PANC.1細(xì)胞、NE1-E6E7細(xì)胞

BayGenomics ES cell line RRS010 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTA263 Cells(提供STR鑒定圖譜)

iBMK BIM+/- B Cells(提供STR鑒定圖譜)

PCRP-NFIL3-2B5 Cells(提供STR鑒定圖譜)

IAR 27F Cells(提供STR鑒定圖譜)

HPSI0514i-suul_2 Cells(提供STR鑒定圖譜)

" "PubMed=1000501

Leibovitz A., Stinson J.C., McCombs W.B. 3rd, McCoy C.E., Mazur K.C., Mabry N.D.

Classification of human colorectal adenocarcinoma cell lines.

Cancer Res. 36:4562-4569(1976)

PubMed=327080; DOI=10.1093/jnci/59.1.221

Fogh J., Fogh J.M., Orfeo T.

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=924690; DOI=10.1002/ijc.2910200505

Kerbel R.S., Pross H.F., Leibovitz A.

Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.

Int. J. Cancer 20:673-679(1977)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=7104989; DOI=10.1016/0165-4608(82)90076-0

Chen T.-R., Hay R.J., Macy M.L.

Karyotype consistency in human colorectal carcinoma cell lines established in vitro.

Cancer Genet. Cytogenet. 6:93-117(1982)

PubMed=6220172

Dracopoli N.C., Fogh J.

Polymorphic enzyme analysis of cultured human tumor cell lines.

J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6652615; DOI=10.1016/0165-4608(83)90092-4

Chen T.-R., Hay R.J., Macy M.L.

Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins.

Cancer Genet. Cytogenet. 10:351-362(1983)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=8422623; DOI=10.1002/1097-0142(19930115)71:2<315::AID-CNCR2820710208>3.0.CO;2-B

Tibbetts L.M., Doremus C.M., Tzanakakis G.N., Vezeridis M.P.

Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production.

Cancer 71:315-321(1993)

PubMed=8464898; DOI=10.1073/pnas.90.7.2842; PMCID=PMC46192

Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G., Bodmer W.F.

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993)

PubMed=8197130; DOI=10.1073/pnas.91.11.4751; PMCID=PMC43866

Bicknell D.C., Rowan A.J., Bodmer W.F.

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)

PubMed=7651727

Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Oncogene 11:647-652(1995)

PubMed=9000572

Hoang J.-M., Cottu P.-H., Thuille B., Salmon R.J., Thomas G., Hamelin R.

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Cancer Res. 57:300-303(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

PubMed=9515795

Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.

Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

Cancer Res. 58:1130-1134(1998)

PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; PMCID=PMC4721570

Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E., Neumann T., Jauho A., Auer G., Ried T.

Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.

Genes Chromosomes Cancer 27:183-190(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11314036; DOI=10.1038/sj.onc.1204211

Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Oncogene 20:1005-1009(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611

Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.-H., Hamelin R.

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Oncogene 20:5025-5032(2001)

PubMed=12615714

Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A., Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D., Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.

Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.

Cancer Res. 63:994-999(2003)

PubMed=16418264; DOI=10.1073/pnas.0510146103; PMCID=PMC1327731

Liu Y., Bodmer W.F.

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

PubMed=19927377; DOI=10.1002/gcc.20730; PMCID=PMC2818350

Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Genes Chromosomes Cancer 49:204-223(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Br. J. Cancer 103:340-346(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=24042735; DOI=10.1038/oncsis.2013.35; PMCID=PMC3816225

Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.

Epigenetic and genetic features of 24 colon cancer cell lines.

Oncogenesis 2:e71.1-e71.8(2013)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

PubMed=29101300; DOI=10.15252/msb.20177701; PMCID=PMC5731344

Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D.J., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.

Pharmacoproteomic characterisation of human colon and rectal cancer.

Mol. Syst. Biol. 13:951-951(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"